COMPARISON OF NETWORK META-ANALYSIS METHODOLOGIES USED TO ASSESS FIRST-LINE TREATMENTS IN RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW

被引：0
|
作者：
Marciniak, A. [1 ]
Orbzut, G. [2 ]
Dlotko, E. [2 ]
Fu, S. [3 ]
Mollon, P. [1 ]
Wallace, J. F. [4 ]
机构：
[1] Ipsen, Boulogne, France
[2] Certara, Krakow, Poland
[3] Certara, Lorrach, BW, Germany
[4] Exelixis Inc, Alameda, CA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA8
引用
收藏
页码：S605 / S606
页数：2
相关论文
共 50 条
  • [41] Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: A systematic review and network meta-analysis
    Quhal, F.
    Mori, K.
    Laukhtina, E.
    Rajwa, P.
    Mostafaei, H.
    Pradere, B.
    Shariat, S. F.
    Schmidinger, M.
    EUROPEAN UROLOGY, 2022, 81 : S591 - S592
  • [42] IMMUNOTHERAPY-BASED COMBINATIONS IN THE FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH SARCOMATOID FEATURES: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Quhal, Fahad
    Mori, Keiichiro
    Laukhtina, Ekaterina
    Pradere, Benjamin
    Mostafaei, Hadi
    Rajwa, Pawel
    Shariat, Shahrokh F.
    Schmidinger, Manuela
    JOURNAL OF UROLOGY, 2022, 207 (05): : E174 - E174
  • [43] Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis
    Larkin, James
    Paine, Abby
    Tumur, Indra
    Cappelleri, Joseph C.
    Healey, Paul J., Sr.
    Foley, Grace
    Mitchell, Stephen
    Kroes, Michel
    Chen, Connie
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 27 - 39
  • [44] Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis
    Zhao, Yang
    Xu, Xiaoqing
    Sun, Yuhan
    Yu, Xinyang
    Qi, Yuanfu
    Dai, Xin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [45] First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis
    Tao, Jiahao
    Zheng, Chuangjie
    Zhang, Cuifen
    Zhou, Ling
    Liu, Zeyu
    Zhou, Yanqun
    Huang, Xuewu
    Lin, Lizhu
    Zhai, Linzhu
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (11)
  • [46] Worldwide and Regional Efficacy Estimates of First-line Helicobacter pylori Treatments A Systematic Review and Network Meta-Analysis
    Zamani, Mohammad
    Alizadeh-Tabari, Shaghayegh
    Zamani, Vahid
    Shokri-Shirvani, Javad
    Derakhshan, Mohammad H.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2022, 56 (02) : 114 - 124
  • [47] NETWORK META-ANALYSIS (NMA) TO ASSESS COMPARATIVE EFFICACY OF LENVATINIB PLUS PEMBROLIZUMAB COMPARED WITH OTHER FIRST-LINE TREATMENTS FOR MANAGEMENT OF ADVANCED RENAL CELL CARCINOMA (ARCC)
    Kadambi, A.
    Pandey, A.
    Neupane, B.
    Fahrbach, K.
    Purushotham, S.
    Jones, M.
    Egodage, S.
    Kashyap, A.
    Pan, J.
    VALUE IN HEALTH, 2022, 25 (07) : S310 - S310
  • [48] First line antiangiogenics for advanced renal cell carcinoma: A systematic review and network meta-analysis comparing efficacy and toxicities
    Kempf, Emmanuelle
    Rousseau, Benoit
    Desamericq, Gaelle
    Boissier, Emilie
    Joly, Charlotte
    Saldana, Carolina
    Chaubet-Houdu, Marie
    Salomon, Laurent
    de la Taille, Alexandre
    Tournigand, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
    Gruenwald, Viktor
    Winquist, Eric
    Peer, Avivit
    Schmidinger, Manuela
    Procopio, Giuseppe
    Barthelemy, Philippe
    Lee, Jae-Lyun
    Rudman, Sarah
    Kadambi, Ananth
    Pandey, Anuja
    Neupane, Binod
    Fahrbach, Kyle
    Purushotham, Sneha
    Jones, Michael
    Egodage, Sonya
    Kashyap, Ananth
    Hauck, Wendy
    Pan, Janice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 482 - 482
  • [50] UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA
    Cakar, E.
    May, J.
    Malcolm, B.
    Gooden, K. M.
    Klijn, S.
    VALUE IN HEALTH, 2019, 22 : S439 - S439
12345